Journal
FUTURE ONCOLOGY
Volume 17, Issue 25, Pages 3291-3299Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-1133
Keywords
metastatic castration-resistant prostate cancer; pembrolizumab
Categories
Funding
- Merck Sharp Dohme Corp.
- Ada Cap (Advanced Accelerator Applications)
- Agensys
- AstraZeneca
- Bayer
- Bristol Myers Squibb
- Clovis Oncology
- Eli Lilly
- Endocyte
- Genentech
- Innocrin Pharma
- MedImmune
- Medivation
- Merck
- Millennium
- Mirati
- Novartis
- Progenics
- Roche
- Sanofi
- Seattle Genetics
- Pfizer Pharmaceuticals, Israel
Ask authors/readers for more resources
Pembrolizumab has shown activity in mCRPC patients as monotherapy and in combination with docetaxel and prednisone/prednisolone. The Phase III KEYNOTE-921 study aims to evaluate the efficacy and safety of pembrolizumab plus docetaxel in mCRPC patients previously treated with an NHA therapy, addressing the unmet need for treatment options in this patient population.
Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit. Thus, an unmet need remains for mCRPC patients after treatment with targeted endocrine therapy or NHA therapy. Pembrolizumab, a humanized monoclonal antibody for PD-1, has been found to have activity as monotherapy in patients with mCRPC and as combination therapy in a Phase Ib/II study with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. The aim of the randomized, double-blind, Phase III KEYNOTE-921 study is to evaluate the efficacy and safety of pembrolizumab plus docetaxel in patients with mCRPC who were previously treated with an NHA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available